Robert J Berman Jr., MD Pediatrics Medicare: Medicare Enrolled Practice Location: 3234 Miller Avenue, Crossville, TN 38555 Phone: 931-707-8700 Fax: 931-456-0802 |
Dr. Suzanne K Berman, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 3234 Miller Ave, Crossville, TN 38555 Phone: 931-707-8700 Fax: 931-456-0802 |
Lauren Elizabeth Fox-bergvin, DO Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3234 Miller Ave, Crossville, TN 38555 Phone: 931-707-8700 Fax: 931-456-0802 |
Christine Reed, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 3234 Miller Ave, Crossville, TN 38555 Phone: 931-707-8700 Fax: 931-456-0802 |
Adaya Alexandra Bayless, CPNP Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3234 Miller Ave, Crossville, TN 38555 Phone: 865-244-0927 Fax: 931-456-0802 |
News Archive
Takeda Pharmaceutical Company Limited announced today that Takeda and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., have completed settlement agreements with six out of eight defendants in patent infringement litigation brought against these parties in response to their Abbreviated New Drug Applications for generic ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl). Takeda recently concluded litigation with the sixth settling defendant.
GE Healthcare, a unit of General Electric Company, in collaboration with Cincinnati Children's Medical Center and the Davis Heart and Lung Institute of The Ohio State University, was awarded $1 million for magnetic resonance imaging and devices for the "Pediatrics Population" project. This project reinforces GE's commitment to healthymagination which works to bring new technologies and solutions to more people.
Bavarian Nordic A/S (OMX: BAVA) announced today that the US authorities have initiated negotiations for a new contract to develop a freeze-dried version of the IMVAMUNE(R) smallpox vaccine.
Adult lifestyle has more influence on your chances of developing diabetes than childhood experience, according to new research whose findings contradict previously-held beliefs.
ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the conclusion of the first Phase II trial testing its unique new hemostat Fibrocaps(TM). Promising preliminary data from the European multicenter, open-label trial show compelling safety and efficacy (time to hemostasis) profiles for Fibrocaps, and good performance of the delivery device.
› Verified 6 days ago